BridgeBio has faced plenty of questions about its “hub-and-spoke" model over the years, but no | BridgeBio has faced plenty of questions about its “hub-and-spoke" model over the years, but now its strategy has yielded the company's first FDA approval. Though the drug isn't expected to be a big mone…